Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Autograft in Patients Undergoing Posterolateral Lumbar Fusion

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorKuros Biosurgery AG

About this trial

This is a phase IV post-marketing study for MagnetOs Easypack Putty. MagnetOs Easypack Putty is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with degenerative disc disease or spinal trauma undergoing spinal fusion surgery.

In this study, MagnetOs Easypack Putty will be used according to the latest U.S. Instructions For Use, standalone in the posterolateral spine.

Eligibility criteria

Qualifiers

Patient is able to read/be read, understand, and provide written informed consent and has signed the Institutional Review Board (IRB) approved informed consent.

Male or female patient ≥ 18 years old.

Patients with segmental mechanical spinal instability requiring arthrodesis surgery.

instability (angulation ≥ 5 degrees or translation ≥ 3 mm on flexion/extension radiographs),

Disqualifiers

Requires > two-level fusion or expected to need secondary intervention within one year following surgery.

Had prior PLF fusion or attempted PLF fusion at the involved levels.

Had previous decompression at the involved levels.

Women who are or intend to become pregnant within the next 12 months.

Trial design

Treatments tested in this trial

  • MagnetOs Easypack Putty
  • Demineralized Bone Matrix or Fibers mixed with local autograft bone

Treatment groups

60 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Kuros Biosurgery AG

Lead sponsor

Simplified Clinical Data Systems, LLC

Collaborator

Kuros BioSciences B.V.

Collaborator